These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 12744613)

  • 1. Immunotherapy of malignant melanoma.
    Kadison AS; Morton DL
    Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
    Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
    Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
    Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
    J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
    van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
    Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
    Jack A; Boyes C; Aydin N; Alam K; Wallack M
    Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant melanoma--future prospects.
    Lugović L; Situm M; Kos L
    Acta Dermatovenerol Croat; 2005; 13(1):36-43. PubMed ID: 15788145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New aspects of immunotherapy of malignant melanoma].
    Enk A
    Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
    Enk AH; Becker JC; Schuler G
    J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic approaches for the treatment of malignant melanoma.
    Curiel-Lewandrowski C; Atkins MB
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Special report: vaccines for the treatment of malignant melanoma.
    Tecnologica MAP Suppl; 2001 Apr; ():19-20. PubMed ID: 11718143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.